Cleaved-LMNA (D230) Antibody

What is Cleaved-LMNA (D230) Antibody and what does it detect?

Cleaved-LMNA (D230) Antibody is a rabbit polyclonal antibody specifically designed to detect fragments of Lamin A and Lamin C proteins that result from proteolytic cleavage at the Aspartate 230 (D230) residue. This antibody recognizes endogenous levels of activated Lamin A protein fragments resulting from cleavage adjacent to D230 . Different variants of this antibody have been developed to target specific fragments:

The antibody is particularly valuable for studying apoptosis, nuclear envelope dynamics, and cellular stress responses that involve Lamin A/C cleavage .

What applications is the Cleaved-LMNA (D230) Antibody suitable for?

Cleaved-LMNA (D230) Antibody has been validated for multiple research applications with specific recommended dilutions:

For optimal results, researchers should perform dilution optimization experiments with their specific cell types or tissue samples . The antibody has been tested and shows reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species .

How should Cleaved-LMNA (D230) Antibody be stored for maximum stability?

To maintain antibody functionality and stability:

• Store at -20°C upon receipt for long-term storage

• For extended preservation, -80°C storage is recommended

• Avoid repeated freeze-thaw cycles that can denature the antibody

• The product is typically formulated in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, which helps maintain stability

• When working with the antibody, aliquot into smaller volumes to minimize freeze-thaw cycles

• Expected shelf life is up to 1 year from date of receipt when stored properly

How can I distinguish between the large and small fragments of cleaved Lamin A in my experiments?

To effectively distinguish between different Lamin A cleavage fragments:

• Antibody selection strategy:

  • Use Cleaved-Lamin A (D230+) antibody to detect large fragments (45-50 kDa)

  • Use Cleaved-Lamin A (D230-) or Cleaved Lamin A (Small Subunit) antibody to detect small fragments (28 kDa)

  • Consider using both antibodies in parallel for comprehensive fragment analysis

• Western blot optimization:

  • Use appropriate polyacrylamide gel percentages (10-12% for large fragments, 15% for small fragments)

  • Include molecular weight markers spanning 20-70 kDa range

  • Optimize transfer conditions based on fragment size (longer transfer times for larger fragments)

  • Use positive controls (e.g., apoptotic cell lysates) to validate fragment detection

• Signal verification:

  • Compare fragment patterns between your experimental conditions and established literature

  • The large fragment (D230+) should appear at approximately 50 kDa for Lamin A and 45 kDa for Lamin C

  • The small fragment (D230-) should appear at approximately 28 kDa

This methodological approach ensures reliable identification and quantification of specific Lamin A cleavage products.

What are the recommended protocols for inducing and detecting Lamin A cleavage in cell culture systems?

For successful Lamin A cleavage induction and detection in cell culture:

• Apoptosis induction methods:

  • Staurosporine treatment (1 μM, 4-6 hours) for broad-spectrum caspase activation

  • TNF-α treatment (50 ng/ml) with cycloheximide (10 μg/ml) for extrinsic pathway activation

  • UV irradiation (50-100 J/m²) for DNA damage-mediated apoptosis

  • Serum starvation (24-48 hours) for physiological apoptosis induction

• Sample preparation protocol:

  • Harvest cells at multiple time points post-induction

  • Wash cells with cold PBS to remove media components

  • Lyse cells with RIPA buffer containing protease inhibitors

  • Quantify protein using BCA or Bradford assay

  • Load 20-30 μg protein per lane for western blot analysis

• Detection optimization:

  • Use 1:500-1:2000 dilution for western blot applications

  • Include both cleaved and total Lamin A/C antibodies for comprehensive analysis

  • Consider using caspase inhibitors (e.g., Z-VAD-FMK) in parallel samples to confirm caspase-dependency

  • Perform time-course experiments to track cleavage progression

This methodological approach enables reliable induction and detection of Lamin A cleavage events in various experimental settings.

How can I optimize immunohistochemistry protocols for detecting cleaved Lamin A in tissue sections?

For optimal IHC detection of cleaved Lamin A in tissue sections:

• Tissue preparation:

  • Fix tissues in 10% neutral-buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Section tissues at 4-5 μm thickness for optimal antibody penetration

  • Use positively charged slides to prevent tissue detachment

• Antigen retrieval methods comparison:

  • Heat-induced epitope retrieval (HIER):

    • Citrate buffer (pH 6.0): 95-100°C for 20 minutes

    • EDTA buffer (pH 9.0): 95-100°C for 20 minutes

    • Compare both methods to determine optimal retrieval for your tissue type

• Antibody incubation protocol:

  • Block endogenous peroxidase with 3% H₂O₂ in methanol (10 minutes)

  • Block non-specific binding with 5% normal goat serum

  • Apply primary antibody at 1:100 dilution (range: 1:50-1:300)

  • Incubate overnight at 4°C in a humidified chamber

  • Use appropriate HRP-conjugated secondary antibody (typically 1:200-1:500)

  • Develop with DAB and counterstain with hematoxylin

• Controls and validation:

  • Include positive control tissue (e.g., apoptotic thymus)

  • Include negative controls (primary antibody omission, isotype control)

  • Consider dual staining with apoptosis markers (e.g., cleaved caspase-3)

This optimized protocol facilitates reliable detection of cleaved Lamin A in various tissue types while minimizing background and maximizing specific signal.

How can I differentiate between apoptotic and other forms of Lamin A cleavage in my experimental results?

To distinguish apoptotic Lamin A cleavage from other proteolytic events:

• Characteristic fragment patterns:

  • Apoptotic cleavage by caspases produces specific fragments:

    • Large fragment (D230+): 45-50 kDa

    • Small fragment (D230-): 28 kDa

  • Non-apoptotic cleavage often produces different fragment sizes

• Confirmatory approaches:

  • Caspase inhibitor studies:

    • Pre-treat cells with pan-caspase inhibitor Z-VAD-FMK (20-50 μM)

    • Compare Lamin A cleavage patterns with and without inhibitor

    • Apoptotic cleavage should be significantly reduced with inhibitor

  • Parallel marker analysis:

    • Simultaneously detect other apoptotic markers (cleaved caspase-3, PARP cleavage)

    • Temporal correlation between these markers supports apoptotic cleavage

    • Absence of other apoptotic markers suggests alternative mechanisms

  • Site-directed mutagenesis validation:

    • Express wild-type and D230A mutant Lamin A in cells

    • Induce apoptosis and compare cleavage patterns

    • D230A mutation should prevent caspase-mediated cleavage at this site

• Alternative cleavage mechanisms to consider:

  • Granzyme B cleavage (during immune cell-mediated cytotoxicity)

  • Viral protease cleavage (during certain viral infections)

  • Autophagy-related degradation (produces different fragment patterns)

This analytical framework helps researchers accurately interpret Lamin A cleavage events in their experimental systems .

What are the most common technical challenges when working with Cleaved-LMNA (D230) Antibody and how can they be resolved?

Researchers frequently encounter these challenges when working with Cleaved-LMNA (D230) Antibody:

• Weak or absent signal in western blots:

  • Problem: Insufficient cleaved product or degradation during sample preparation

  • Solutions:

    • Ensure adequate apoptosis induction (verify with positive controls)

    • Add protease inhibitor cocktail to lysis buffer immediately before use

    • Reduce sample processing time and keep samples cold

    • Optimize antibody concentration (try 1:500 instead of 1:2000)

    • Increase protein loading (30-40 μg) and exposure time

• High background in immunohistochemistry:

  • Problem: Non-specific binding or excessive primary antibody

  • Solutions:

    • Optimize blocking (try 5% BSA or 10% normal serum from secondary host)

    • Dilute primary antibody further (1:200-1:300)

    • Increase washing steps (5×5 minutes with 0.1% Tween-20 in PBS)

    • Use more specific secondary antibody

    • Preabsorb antibody with tissue powder if needed

• False positive results:

  • Problem: Cross-reactivity with other cleaved proteins

  • Solutions:

    • Perform peptide competition assay to confirm specificity

    • Include LMNA-knockout samples as negative controls

    • Verify results with alternative antibody clones

    • Confirm fragment size matches expected molecular weight (28 kDa for small fragment, 45-50 kDa for large fragment)

• Inconsistent results between experiments:

  • Problem: Variability in antibody performance or sample preparation

  • Solutions:

    • Aliquot antibody to avoid freeze-thaw cycles

    • Standardize lysis buffer composition and incubation times

    • Use consistent positive controls across experiments

    • Normalize data to housekeeping proteins (GAPDH)

These troubleshooting approaches help overcome common technical challenges when working with Cleaved-LMNA (D230) Antibody.

How can Cleaved-LMNA (D230) Antibody be utilized in studying nuclear envelope dynamics during cellular stress?

Advanced applications for studying nuclear envelope dynamics with Cleaved-LMNA (D230) Antibody:

• Live-cell imaging approaches:

  • Methodology:

    • Co-express fluorescently tagged Lamin A with nuclear envelope markers

    • Apply cellular stressors (oxidative stress, mechanical stress, heat shock)

    • Fix cells at various timepoints and immunostain with Cleaved-LMNA (D230) antibody

    • Analyze using high-resolution confocal or super-resolution microscopy

  • Data analysis:

    • Quantify co-localization between cleaved fragments and nuclear envelope markers

    • Track temporal changes in nuclear morphology and cleaved Lamin A distribution

    • Correlate cleavage events with nuclear envelope rupture or blebbing

• Proximity ligation assay (PLA) applications:

  • Methodology:

    • Combine Cleaved-LMNA (D230) antibody with antibodies against nuclear pore complex proteins

    • Perform PLA to detect interactions between cleaved lamins and other nuclear envelope components

    • Analyze PLA signals to quantify molecular proximity during stress responses

  • Advantage: Detects protein interactions at endogenous expression levels with high sensitivity

• Chromatin association analysis:

  • Methodology:

    • Perform ChIP-seq using Cleaved-LMNA (D230) antibody

    • Map genomic regions associated with cleaved Lamin A fragments

    • Compare with lamin-associated domains (LADs) identified with intact Lamin A

  • Insights: Reveals how lamin cleavage affects chromatin organization and gene expression

• Correlative light and electron microscopy (CLEM):

  • Methodology:

    • Immunolabel stressed cells with Cleaved-LMNA (D230) antibody for fluorescence microscopy

    • Process the same samples for electron microscopy

    • Correlate cleaved Lamin A localization with ultrastructural changes in the nuclear envelope

  • Advantage: Provides both molecular specificity and nanoscale structural context

These advanced applications extend beyond basic detection to reveal fundamental mechanisms of nuclear envelope dynamics during cellular stress responses .

What are the current methodologies for using Cleaved-LMNA (D230) Antibody in studying age-related diseases and progeria syndromes?

Advanced methodological approaches for studying age-related diseases and progeria using Cleaved-LMNA (D230) Antibody:

• Patient-derived cell models:

  • Protocol framework:

    • Isolate fibroblasts from Hutchinson-Gilford Progeria Syndrome (HGPS) patients

    • Culture matched control and HGPS fibroblasts under identical conditions

    • Analyze baseline and stress-induced Lamin A cleavage patterns using Cleaved-LMNA (D230) antibody

    • Compare D230 cleavage with progerin accumulation using dual immunostaining

  • Analytical measures:

    • Quantify ratio of cleaved to total Lamin A across different passage numbers

    • Correlate cleavage patterns with nuclear morphology abnormalities

    • Assess cell sensitivity to apoptosis inducers

• Tissue microarray analysis of aging tissues:

  • Methodology:

    • Prepare tissue microarrays from young vs. aged tissues or normal vs. disease samples

    • Perform immunohistochemistry with Cleaved-LMNA (D230) antibody (1:100 dilution)

    • Quantify positive nuclear staining using digital pathology software

    • Correlate findings with senescence markers and tissue pathology

  • Advantage: Enables high-throughput analysis across multiple tissue types and conditions

• Targeted intervention studies:

  • Experimental design:

    • Treat progeria or aged cell models with potential therapeutic compounds

    • Assess changes in Lamin A cleavage patterns using Western blot (1:500-1:2000 dilution)

    • Compare effects of treatments targeting different pathways:

      • Farnesyltransferase inhibitors

      • Autophagy modulators

      • Caspase inhibitors

      • Antioxidants

  • Outcome measures:

    • Changes in D230 cleavage frequency

    • Nuclear morphology restoration

    • Correlation with cell viability and function

• Animal model applications:

  • Methodology:

    • Analyze tissues from progeria mouse models (Lmna G609G) at different ages

    • Perform Western blot and immunohistochemistry using Cleaved-LMNA (D230) antibody

    • Compare with tissues from naturally aged animals

    • Correlate with physiological aging parameters

  • Technical considerations:

    • Use appropriate secondary antibodies for mouse tissue (to avoid cross-reactivity)

    • Include proper controls to distinguish specific signal from background

    • Analyze multiple tissue types to identify tissue-specific differences

These methodological approaches provide comprehensive frameworks for investigating the role of Lamin A cleavage in normal and pathological aging processes .

How can multiplexed detection systems be optimized when using Cleaved-LMNA (D230) Antibody alongside other apoptosis markers?

Advanced protocols for multiplexed detection with Cleaved-LMNA (D230) Antibody:

• Multiplex immunofluorescence optimization:

  • Panel design strategy:

    • Cleaved-LMNA (D230) antibody (rabbit polyclonal, 1:50-1:200)

    • Cleaved Caspase-3 antibody (mouse monoclonal)

    • PARP cleavage marker (goat polyclonal)

    • Nuclear counterstain (DAPI)

  • Technical optimization:

    • Sequential antibody application to minimize cross-reactivity

    • Careful selection of fluorophores to minimize spectral overlap

    • Use of spectral unmixing for closely overlapping signals

    • Implement tyramide signal amplification for low-abundance targets

  • Validation controls:

    • Single-color controls for accurate compensation

    • FMO (fluorescence minus one) controls to set gating boundaries

    • Peptide competition controls to confirm specificity

• Mass cytometry (CyTOF) integration:

  • Protocol framework:

    • Metal-conjugate Cleaved-LMNA (D230) antibody with rare earth metals

    • Create comprehensive apoptosis panel including:

      • Initiator caspases (metal-tagged anti-cleaved caspase-8/9)

      • Executioner caspases (metal-tagged anti-cleaved caspase-3/7)

      • Mitochondrial markers (metal-tagged anti-cytochrome c)

      • Cleaved-LMNA (D230) as nuclear envelope marker

    • Analyze using standard mass cytometry workflows

  • Advantage: Allows simultaneous detection of 30+ markers without fluorescence spectrum limitations

• Imaging mass cytometry application:

  • Methodology:

    • Prepare tissue sections according to standard protocols

    • Apply metal-conjugated antibody panel including Cleaved-LMNA (D230)

    • Acquire data using imaging mass cytometry system

    • Analyze spatial relationships between apoptotic markers at subcellular resolution

  • Data analysis approach:

    • Perform neighborhood analysis to identify spatial relationships

    • Quantify co-occurrence of cleaved Lamin A with other apoptotic events

    • Map temporal sequences of apoptotic marker activation

• Digital spatial profiling integration:

  • Workflow:

    • Design custom panel including Cleaved-LMNA (D230) antibody

    • Perform multispectral imaging on tissue sections

    • Use digital spatial profiling to quantify marker expression in specific regions

    • Correlate Cleaved-LMNA with other markers at single-cell resolution

  • Advantage: Combines spatial context with high-plex protein quantification

These advanced multiplexing approaches enable comprehensive analysis of apoptotic processes while maintaining spatial context and single-cell resolution .

How can Cleaved-LMNA (D230) Antibody be used to investigate caspase activation patterns in neurodegenerative disease models?

Methodological framework for investigating neurodegenerative diseases using Cleaved-LMNA (D230) Antibody:

• In vitro neurodegenerative disease models:

  • Experimental setup:

    • Culture primary neurons or neuronal cell lines (e.g., SH-SY5Y, Neuro2A)

    • Apply disease-relevant stressors:

      • Amyloid-β peptides (Alzheimer's disease model)

      • MPP+ (Parkinson's disease model)

      • Mutant huntingtin expression (Huntington's disease model)

    • Harvest cells at multiple timepoints (4, 8, 12, 24 hours)

    • Perform Western blot with Cleaved-LMNA (D230) antibody (1:500-1:2000)

  • Comparative analysis:

    • Quantify cleaved Lamin A fragments relative to total Lamin A

    • Compare with activation patterns of initiator (caspase-8/9) and executioner caspases (caspase-3/7)

    • Correlate with markers of neuronal dysfunction

• Brain tissue analysis protocol:

  • Sample preparation:

    • Collect brain tissue from disease models and age-matched controls

    • Prepare protein extracts from specific brain regions

    • Alternatively, prepare formalin-fixed paraffin-embedded sections

  • Detection methods:

    • Western blot: Use Cleaved-LMNA (D230-) antibody to detect 28 kDa fragment

    • Immunohistochemistry: Use 1:100 dilution for optimal tissue staining

    • Dual immunofluorescence: Combine with neuronal markers and other apoptosis indicators

  • Quantification approach:

    • Count percentage of neurons showing nuclear Cleaved-LMNA positivity

    • Measure intensity of staining relative to disease progression

    • Perform region-specific analysis to identify vulnerable neuronal populations

• Intervention studies design:

  • Treatment strategy:

    • Apply neuroprotective compounds or caspase inhibitors to disease models

    • Use Cleaved-LMNA (D230) antibody as a marker of intervention efficacy

    • Compare early vs. late intervention timepoints

  • Readout measures:

    • Reduction in Cleaved-LMNA signal as primary marker of reduced apoptosis

    • Correlation with functional outcomes and neuronal survival

    • Comparison with other apoptotic markers to identify pathway-specific effects

• Advanced molecular imaging:

  • 3D tissue clearing and imaging:

    • Apply tissue clearing methods (CLARITY, iDISCO) to intact brain samples

    • Perform whole-mount immunostaining with Cleaved-LMNA (D230) antibody

    • Image using light-sheet microscopy

    • Reconstruct 3D patterns of neuronal apoptosis across brain regions

  • Advantage: Preserves spatial relationships and enables whole-organ analysis

These methodological approaches enable systematic investigation of caspase activation patterns in neurodegenerative diseases using Cleaved-LMNA (D230) Antibody as a key molecular marker .

What are the current best practices for using Cleaved-LMNA (D230) Antibody in cancer research applications?

Comprehensive methodological framework for cancer research applications with Cleaved-LMNA (D230) Antibody:

• Treatment response monitoring in cancer cell lines:

  • Experimental protocol:

    • Culture appropriate cancer cell lines (e.g., MCF-7, HeLa, A549)

    • Treat with chemotherapeutic agents at clinically relevant concentrations:

      • DNA-damaging agents (cisplatin, doxorubicin)

      • Microtubule inhibitors (paclitaxel, vincristine)

      • Targeted therapies (tyrosine kinase inhibitors, PARP inhibitors)

    • Harvest cells at multiple timepoints (6, 12, 24, 48 hours)

    • Perform Western blot with 1:1000 dilution of Cleaved-LMNA (D230) antibody

  • Analytical considerations:

    • Quantify the ratio of cleaved to total Lamin A/C

    • Correlate with other apoptotic markers and cell viability

    • Compare patterns across drug classes to identify mechanism-specific differences

• Patient-derived xenograft (PDX) analysis:

  • Tissue processing workflow:

    • Collect tumor tissue before and after treatment

    • Prepare formalin-fixed, paraffin-embedded sections

    • Perform immunohistochemistry using 1:100 dilution

    • Counterstain with hematoxylin for nuclear visualization

  • Quantification approach:

    • Score percentage of tumor cells positive for Cleaved-LMNA

    • Analyze spatial distribution (tumor core vs. periphery)

    • Correlate with treatment response and patient outcome data

• Resistance mechanism investigation:

  • Comparative study design:

    • Establish drug-sensitive and resistant cell line pairs

    • Analyze baseline and drug-induced Lamin A cleavage patterns

    • Use Western blot (1:500-1:2000) and immunofluorescence (1:50-1:200)

  • Mechanistic analysis:

    • Correlate altered Lamin A cleavage with:

      • Changes in caspase expression/activity

      • Alterations in nuclear envelope structure

      • DNA damage response patterns

    • Perform genetic manipulation (CRISPR/siRNA) of apoptotic pathway components to confirm mechanism

• Multidimensional analysis of tumor heterogeneity:

  • Single-cell analysis protocol:

    • Prepare single-cell suspensions from tumor samples

    • Perform multiparameter flow cytometry including Cleaved-LMNA staining

    • Analyze subpopulations based on apoptotic sensitivity

  • Spatial analysis in tissue:

    • Perform multiplex immunofluorescence with Cleaved-LMNA antibody and cancer stem cell markers

    • Map spatial relationship between apoptosis-resistant and sensitive regions

    • Correlate with hypoxia markers and stromal components

These methodological approaches provide comprehensive frameworks for investigating apoptosis resistance mechanisms and treatment responses in cancer research using Cleaved-LMNA (D230) Antibody .

How can researchers differentiate between Cleaved-LMNA (D230) Antibody signals and other nuclear envelope-associated markers in complex tissue samples?

Methodological approach for differential analysis of nuclear envelope markers:

• Antibody specificity verification:

  • Sequential immunodepletion protocol:

    • Pre-incubate tissue sections with unlabeled antibodies against other nuclear envelope components

    • Follow with Cleaved-LMNA (D230) antibody staining

    • Compare staining pattern with and without depletion

  • Peptide competition assay:

    • Pre-incubate Cleaved-LMNA (D230) antibody with specific immunogen peptide

    • Apply to adjacent tissue sections

    • True positive signal should be abolished by peptide competition

• Advanced co-localization analysis:

  • Multiplexed immunofluorescence protocol:

    • Apply Cleaved-LMNA (D230) antibody (1:50-1:200)

    • Co-stain with antibodies against:

      • Lamin B1 (intact nuclear lamina marker)

      • Nuclear pore complex proteins (e.g., NUP98)

      • Emerin (inner nuclear membrane marker)

      • Cleaved caspase-3 (apoptosis marker)

    • Image using confocal or super-resolution microscopy

  • Quantitative analysis approach:

    • Calculate Pearson's correlation coefficients between markers

    • Perform intensity profile analysis across nuclear envelope

    • Apply nearest neighbor analysis to determine spatial relationships

    • Use supervised machine learning for pattern recognition in complex tissues

• Super-resolution microscopy optimization:

  • Sample preparation protocol:

    • Fix cells using 4% paraformaldehyde (10 minutes, room temperature)

    • Permeabilize with 0.1% Triton X-100 (5 minutes)

    • Block with 3% BSA in PBS (1 hour)

    • Apply Cleaved-LMNA (D230) antibody at 1:100 dilution

    • Use fluorophore-conjugated secondary antibodies optimized for super-resolution

  • Imaging considerations:

    • Structured illumination microscopy (SIM): ~120 nm resolution

    • Stimulated emission depletion (STED): ~50 nm resolution

    • Single-molecule localization microscopy: ~20 nm resolution

  • Advantage: Enables precise localization and differentiation between closely associated nuclear envelope components

• Chromatin immunoprecipitation sequencing (ChIP-seq) comparative analysis:

  • Methodology:

    • Perform ChIP-seq with Cleaved-LMNA (D230) antibody

    • Compare binding patterns with intact Lamin A and other nuclear envelope proteins

    • Identify unique genomic associations of cleaved fragments

  • Bioinformatic analysis:

    • Generate heatmaps of binding patterns across genomic features

    • Perform motif analysis to identify sequence preferences

    • Compare with gene expression data to identify functional associations

These advanced analytical approaches enable precise differentiation between Cleaved-LMNA signals and other nuclear envelope components in complex tissue samples .

What quantitative approaches can be used to analyze Western blot data generated using Cleaved-LMNA (D230) Antibody in apoptosis research?

Comprehensive quantitative framework for Western blot analysis:

• Standardized densitometric analysis protocol:

  • Sample preparation standardization:

    • Load equal protein amounts (20-30 μg) verified by BCA assay

    • Include consistent positive controls across experiments

    • Use recombinant cleaved fragment standards for absolute quantification

  • Technical optimization:

    • Use 1:1000 dilution of Cleaved-LMNA (D230) antibody for consistent detection

    • Optimize exposure times to ensure linear dynamic range

    • Perform replicate blots to assess technical variability

  • Quantification workflow:

    • Normalize cleaved fragment signal to GAPDH or β-actin loading controls

    • Calculate cleavage ratio: Cleaved Fragment / (Cleaved Fragment + Intact Protein)

    • Perform statistical analysis across biological replicates (n≥3)

• Multiplex Western blot analytical approach:

  • Experimental setup:

    • Use fluorescent secondary antibodies with different spectral properties

    • Simultaneously detect:

      • Cleaved Lamin A (D230-) fragment (28 kDa)

      • Cleaved Lamin A (D230+) fragment (45-50 kDa)

      • Total Lamin A/C

      • GAPDH (loading control)

    • Image using multi-channel fluorescence scanner

  • Quantitative advantages:

    • Direct comparison of multiple proteins on same membrane

    • Elimination of stripping and reprobing variability

    • Extended linear dynamic range compared to chemiluminescence

    • More precise normalization to loading controls

• Time-course kinetic analysis:

  • Experimental design:

    • Collect samples at multiple timepoints after apoptosis induction

    • Perform Western blot with Cleaved-LMNA (D230) antibody at 1:500-1:2000

    • Plot time-dependent changes in fragment appearance

  • Mathematical modeling:

    • Fit data to first-order kinetic models

    • Calculate rate constants for Lamin A cleavage

    • Compare with kinetics of upstream caspase activation

    • Develop predictive models of apoptotic progression

• Digital Western blot technologies:

  • Methodology:

    • Utilize automated Western platforms (e.g., Jess, Wes systems)

    • Perform capillary-based size separation followed by immunodetection

    • Use Cleaved-LMNA (D230) antibody at manufacturer-recommended dilutions

  • Analytical advantages:

    • Higher reproducibility through automation

    • Lower sample volume requirements

    • Extended quantitative dynamic range

    • Automated analysis with minimal user bias

These quantitative approaches enable rigorous analysis of Western blot data generated with Cleaved-LMNA (D230) Antibody, providing more reliable and reproducible results in apoptosis research .